Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib versus best available therapy in thrombocytopenic myelofibrosis
2013-004000-19Phase 3Terminated
- Sponsor
- CTI BioPharma Corp.
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pacritinib in myelofibrosis (MF) (3 arms), sponsored by CTI BioPharma Corp. Primary endpoint: Spleen volume response at Week 24. Started Feb 2014; status: terminated.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2013-004000-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004000-19.